C
Concord Biotech Ltd
NSE:CONCORDBIO
Concord Biotech Ltd
NSE:CONCORDBIO
Price:
1 100
INR
-0.09%
Market Closed
Market Cap:
₹115.1B
Balance Sheet
Balance Sheet Decomposition
Concord Biotech Ltd
Concord Biotech Ltd
Balance Sheet Decomposition is not available for
Concord Biotech Ltd
Concord Biotech Ltd
Balance Sheet
Concord Biotech Ltd
Concord Biotech Ltd
Currency: INR
| Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
26
|
608
|
889
|
434
|
470
|
12
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
9
|
|
| Cash Equivalents |
26
|
608
|
889
|
434
|
470
|
3
|
|
| Short-Term Investments |
1 982
|
1 411
|
739
|
1 663
|
2 665
|
3 345
|
|
| Total Receivables |
2 113
|
2 153
|
2 420
|
2 933
|
3 789
|
5 475
|
|
| Accounts Receivables |
1 836
|
1 790
|
2 343
|
2 745
|
3 508
|
5 217
|
|
| Other Receivables |
277
|
363
|
77
|
188
|
280
|
258
|
|
| Inventory |
1 127
|
1 550
|
1 976
|
2 136
|
2 156
|
2 412
|
|
| Other Current Assets |
139
|
350
|
302
|
111
|
201
|
111
|
|
| Total Current Assets |
5 386
|
6 071
|
6 327
|
7 277
|
8 962
|
11 352
|
|
| PP&E Net |
3 809
|
5 577
|
6 436
|
7 655
|
7 865
|
8 442
|
|
| PP&E Gross |
3 809
|
5 577
|
6 436
|
7 655
|
7 865
|
8 442
|
|
| Accumulated Depreciation |
692
|
924
|
1 378
|
1 873
|
2 401
|
2 904
|
|
| Intangible Assets |
1
|
64
|
36
|
2
|
3
|
11
|
|
| Note Receivable |
0
|
17
|
36
|
27
|
125
|
110
|
|
| Long-Term Investments |
62
|
31
|
28
|
103
|
31
|
348
|
|
| Other Long-Term Assets |
147
|
64
|
266
|
76
|
22
|
79
|
|
| Total Assets |
9 405
N/A
|
11 825
+26%
|
13 128
+11%
|
15 140
+15%
|
17 007
+12%
|
20 343
+20%
|
|
| Liabilities | |||||||
| Accounts Payable |
712
|
464
|
831
|
938
|
944
|
1 130
|
|
| Accrued Liabilities |
0
|
5
|
4
|
3
|
1
|
0
|
|
| Short-Term Debt |
0
|
51
|
43
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
136
|
263
|
266
|
251
|
79
|
23
|
|
| Other Current Liabilities |
303
|
274
|
408
|
726
|
398
|
687
|
|
| Total Current Liabilities |
1 151
|
1 057
|
1 552
|
1 918
|
1 422
|
1 841
|
|
| Long-Term Debt |
385
|
579
|
316
|
64
|
19
|
6
|
|
| Deferred Income Tax |
151
|
175
|
210
|
234
|
281
|
340
|
|
| Other Liabilities |
16
|
21
|
19
|
23
|
20
|
28
|
|
| Total Liabilities |
1 703
N/A
|
1 832
+8%
|
2 096
+14%
|
2 240
+7%
|
1 741
-22%
|
2 215
+27%
|
|
| Equity | |||||||
| Common Stock |
95
|
95
|
95
|
105
|
105
|
105
|
|
| Retained Earnings |
6 778
|
9 069
|
10 108
|
11 976
|
14 342
|
17 203
|
|
| Additional Paid In Capital |
829
|
829
|
829
|
820
|
820
|
820
|
|
| Other Equity |
0
|
0
|
0
|
0
|
15 162
|
18 023
|
|
| Total Equity |
7 702
N/A
|
9 994
+30%
|
11 032
+10%
|
12 900
+17%
|
15 266
+18%
|
18 127
+19%
|
|
| Total Liabilities & Equity |
9 405
N/A
|
11 825
+26%
|
13 128
+11%
|
15 140
+15%
|
17 007
+12%
|
20 343
+20%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
105
|
105
|
105
|
105
|
105
|
105
|
|
Switch to:
Switch to:
See Also
Discover More
